These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30471270)

  • 1. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
    Strollo PJ; Hedner J; Collop N; Lorch DG; Chen D; Carter LP; Lu Y; Lee L; Black J; Pépin JL; Redline S;
    Chest; 2019 Feb; 155(2):364-374. PubMed ID: 30471270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
    Schweitzer PK; Mayer G; Rosenberg R; Malhotra A; Zammit GK; Gotfried M; Chandler P; Baladi M; Strohl KP
    Chest; 2021 Jul; 160(1):307-318. PubMed ID: 33631141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A; Shapiro C; Pepin JL; Hedner J; Ahmed M; Foldvary-Schaefer N; Strollo PJ; Mayer G; Sarmiento K; Baladi M; Chandler P; Lee L; Schwab R
    Sleep; 2020 Feb; 43(2):. PubMed ID: 31691827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ; Shapiro C; Mayer G; Corser BC; Emsellem H; Plazzi G; Chen D; Carter LP; Wang H; Lu Y; Black J; Dauvilliers Y
    Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
    Schweitzer PK; Rosenberg R; Zammit GK; Gotfried M; Chen D; Carter LP; Wang H; Lu Y; Black J; Malhotra A; Strohl KP;
    Am J Respir Crit Care Med; 2019 Jun; 199(11):1421-1431. PubMed ID: 30521757
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
    Rosenberg R; Baladi M; Bron M
    J Clin Sleep Med; 2021 Apr; 17(4):711-717. PubMed ID: 33226332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
    CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R; Thorpy MJ; Dauvilliers Y; Schweitzer PK; Zammit G; Gotfried M; Bujanover S; Scheckner B; Malhotra A
    J Clin Sleep Med; 2022 Jan; 18(1):235-244. PubMed ID: 34283019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
    Ronnebaum S; Bron M; Patel D; Menno D; Bujanover S; Kratochvil D; Lucas E; Stepnowsky C
    J Clin Sleep Med; 2021 Dec; 17(12):2543-2555. PubMed ID: 34402784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Videnovic A; Amara AW; Comella C; Schweitzer PK; Emsellem H; Liu K; Sterkel AL; Gottwald MD; Steinerman JR; Jochelson P; Zomorodi K; Hauser RA
    Mov Disord; 2021 Oct; 36(10):2408-2412. PubMed ID: 34191352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
    Ruoff C; Swick TJ; Doekel R; Emsellem HA; Feldman NT; Rosenberg R; Bream G; Khayrallah MA; Lu Y; Black J
    Sleep; 2016 Jul; 39(7):1379-87. PubMed ID: 27166238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.
    Schweitzer PK; Strohl KP; Mayer G; Rosenberg R; Chandler P; Baladi M; Lee L; Malhotra A
    J Clin Sleep Med; 2021 Apr; 17(4):659-668. PubMed ID: 33179591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
    Krystal AD; Benca RM; Rosenberg R; Schweitzer PK; Malhotra A; Babson K; Lee L; Bujanover S; Strohl KP
    J Psychiatr Res; 2022 Nov; 155():202-210. PubMed ID: 36070638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
    Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
    Weaver TE; Pepin JL; Schwab R; Shapiro C; Hedner J; Ahmed M; Foldvary-Schaefer N; Strollo PJ; Mayer G; Sarmiento K; Baladi M; Bron M; Chandler P; Lee L; Malhotra A
    J Clin Sleep Med; 2021 Oct; 17(10):1995-2007. PubMed ID: 34606437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R; Singh R; Thakur RK; K C B; Jha D; Ray BK
    Sleep Med; 2020 Nov; 75():510-521. PubMed ID: 33032062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials.
    Wang J; Yang S; Li X; Wang T; Xu Z; Xu X; Gao H; Chen G
    Sleep Med; 2021 Mar; 79():40-47. PubMed ID: 33472129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
    Bogan RK; Feldman N; Emsellem HA; Rosenberg R; Lu Y; Bream G; Khayrallah M; Lankford DA
    Sleep Med; 2015 Sep; 16(9):1102-8. PubMed ID: 26298786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.
    Pitre T; Mah J; Roberts S; Desai K; Gu Y; Ryan C; Busse JW; Zeraatkar D
    Ann Intern Med; 2023 May; 176(5):676-684. PubMed ID: 37155992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC
    Nat Sci Sleep; 2021; 13():75-91. PubMed ID: 33531850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.